二甲双胍与生存:在仅限于患有子宫内膜癌、乳腺癌或卵巢癌的糖尿病女性队列中是否有获益?
该队列纳入2010至2019年新诊断卵巢癌、乳腺癌或子宫内膜癌的6225例2型糖尿病女性,按ADA指南将降糖药分为3层,比较二甲双胍与未用药、2层药及3层药的生存差异。二甲双胍使用最多(n=3232),在所有方法中均较2层和3层药物显示生存获益;3层药使用者较二甲双胍死亡风险最高。
要点
- 二甲双胍是使用最多的降糖药(n=3232),在所有分析方法中均较2层和3层药物显示生存获益。
- 3层药使用者较二甲双胍的死亡风险为adjHR=1.83(95%CI:1.58,2.13),较2层药为adjHR=1.32(95%CI:1.11,1.57)。
- 作者认为,即使校正糖尿病进展的替代指标后,二甲双胍使用仍与生存改善相关,且获益超出2层药使用者所见。
核心结论
- 二甲双胍使用者在校正糖尿病进展的替代指标后仍观察到生存改善,且获益超出2层药使用者所见。
- 作者认为,研究结果与既往研究一致,提示二甲双胍使用可改善2型糖尿病合并激素介导的女性癌症患者的生存。
研究设计与样本
- 评估2010至2019年新诊断卵巢癌、乳腺癌或子宫内膜癌的6225例2型糖尿病女性队列的结局。
- 按ADA指南将首次癌症诊断时的降糖药物分为3层,比较二甲双胍(1层)与未用降糖药、二甲双胍与2层药、二甲双胍与3层药、2层药与3层药。
- 分析包括Cox比例风险模型、Kaplan-Meier曲线及按2型糖尿病病程匹配的风险集抽样嵌套病例对照的条件logistic回归,均建模生存。
- 模型校正人口学特征、癌症类型、A1C、2型糖尿病病程及就诊和住院次数。
主要发现
- 二甲双胍是使用最多的药物(n=3232),在所有方法中均较2层和3层药物显示生存获益。
- 3层药使用者较二甲双胍的死亡风险为adjHR=1.83(95%CI:1.58,2.13),较2层药为adjHR=1.32(95%CI:1.11,1.57)。
- 尽管1层和2层药使用者的基线特征相似,3层药使用者较二甲双胍的死亡风险高于2层药使用者较二甲双胍的死亡风险。
关键数值与推荐
- 降糖药物按ADA指南分为3层:1层为二甲双胍;2层包括磺脲类、噻唑烷二酮类、SGLT2抑制剂、DPP4抑制剂、α葡萄糖苷酶抑制剂、GLP-1激动剂;3层包括胰岛素、淀粉样肽类似物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate the association between metformin and survival in women with Type 2 diabetes (T2DM) and breast, endometrial and ovarian cancer- 3 hormonally mediated cancers. METHODS: We evaluated outcomes in a cohort of 6225 women with T2DM with a new diagnosis of ovarian, breast or endometrial cancer from 2010 to 2019. We classified glycemic medications at time of first cancer diagnosis into 3 tiers in accordance with ADA guidelines. Approaches compared: (i) metformin (tier 1) vs. no glycemic medication, (ii) metformin vs tier 2 medications (sulfonylureas, thiazolidinediones, SGLT2-inhibitors, DPP4-inhibitors, alpha glucosidase-inhibitors, GLP-1 agonists), (iii) metformin vs tier 3 medications (insulins, amylinomimetics), and (iv) tier 2 vs tier 3 medications. Analyses included Cox proportional-hazards models, Kaplan-Meier curves, and conditional logistic regression in a risk set-sampled nested case-control matched on T2DM duration- all modeling survival. Models were adjusted for demographics, cancer type, A1C, T2DM duration, and number of office visits and hospitalizations. RESULTS: Metformin was the most used medication (n = 3232) and consistently demonstrated survival benefit compared with tier 2 and 3 medications, across all methods. Tier 3-users demonstrated highest risk of death when compared to metformin rather than tier 2 [adjHR = 1.83 (95% CI: 1.58, 2.13) vs. adjHR = 1.32 (95% CI: 1.11, 1.57)], despite similar baseline profiles between tier 1 and 2 users. CONCLUSIONS: Metformin users experienced increased survival even after accounting for surrogates of diabetes progression. Benefit extended beyond that seen in tier 2-users. Our findings, consistent with prior studies, indicate metformin use improves survival in women with T2DM and hormonally mediated women's cancers.
引用
- Lemon LS, Orr B, Modugno F, et al. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Gynecol Oncol. 2022. PMID: 35140015. doi:10.1016/j.ygyno.2022.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。